tbuckley/cabot-search huggingface dataset:
The knowledge and practices of urologists in the United States (US) about standardization of PSA assays.
Authors: A. Gupta, S. F. Shariat, J. A. Eastham, P. T. Scardino, A. J. Vickers, H. Lilja
Journal: Journal of Clinical Oncology (2011)

207 Background: PSA assays can be calibrated to either the WHO or the Hybritech standard. Studies of PSA-based prostate cancer screening have used Hybritech-standardized assays and prostate cancer risk calculators are based on these studies. Testing of patient samples with a WHO calibrated assay gives values that are 22% lower than from those with Hybritech-calibrated assays. Up to 60% of the labs in the US use WHO calibrated assays. We evaluated whether US urologists are aware of the different calibrators and the differences in PSA values. Methods: A random sample of 1,742 US urologists were invited by email to participate in a web-based survey of their knowledge and practices regarding PSA assay standardization. No mention was made of assays or calibration in the invitation. 419 responses were received. Results: Many (56%) US urologists thought that different standards may lead to clinically relevant differences in PSA values. Although 62% reported awareness of the two PSA calibrators, 67% did not know the difference between the two. Only 17% correctly reported the difference between the two standards. Nationally almost 60% of the labs use WHO standardized assays, but in this survey only 5% of the urologists thought that the hospital where they practice used a WHO standardized assay. The rest reported either not knowing the standard (46%) or use of the Hybritech standard (49%). The majority of urologists did not look at the reference range (64%) or for the PSA standard (74%) in the lab reports. Only 25% reported considering the PSA-calibration in their clinical decisions about prostate biopsy, but only a third of them correctly knew the difference between the calibrators. Conclusions: Many US urologists are unaware of the difference caused by WHO versus Hybritech based PSA-assay calibration. Although 60% of clinical laboratories use WHO-calibrated assays, only 5% of urologists are aware of this use in their practice, and a majority of urologists could not correctly explain the difference between the different calibrators. A greater awareness is needed amongst US urologists about the different PSA calibrators, the calibrator in use at their practice, and means to account for different calibrators in clinical decision making. [Table: see text]
Evidence for A Macromolecular Complex in Poor Prognostic CLL That Contains CD38, CD49d, CD44, MMP-9 and ZAP-70.
Authors: Andrea Gail Sherman Buggins, Ana Levi, Satyen Gohil, Keith Fishlock, Piers EM Patten, Deborah Yallop, Ghulam J Mufti, Stephen Devereux
Journal: Blood (2009)
LP38 : Efficacy and safety of IFN-free antiviral therapy in patients with HCV recurrence after liver transplantation: real-life experience from austria
Authors: S. Beinhardt, C. Freissmuth, R. Al-Zoairy, K. Kozbial, S. Hametner, R. Stern, R. Stauber, A. Maieron, K. Staufer, M. Strasser, H. Zoller, I. Graziadei, W. Vogel, M. Peck-Radosavljevic, M. Trauner, P. Ferenci, H. Hofer
Journal: Journal of Hepatology (2015)
Comparing survival with breast-conservation therapy or mastectomy in the management of young women with early-stage breast cancer.
Authors: U. Mahmood, C. G. Morris, G. A. Neuner, M. Koshy, S. Kesmodel, R. Buras, S. Chumsri, T. Bao, K. H. Tkaczuk, S. J. Feigenberg
Journal: Journal of Clinical Oncology (2011)

85 Background: Previous studies have shown that young women with breast cancer treated with breast-conservation therapy (BCT) experience higher local recurrence rates. Whether such patients are better treated with mastectomy is unclear. The purpose of this study was to evaluate survival outcomes of young women with early-stage breast cancer treated with BCT or mastectomy using a large, population-based database. Methods: Using the Surveillance, Epidemiology, and End Results (SEER) database, information was obtained for all female patients age 20 to 39 diagnosed with T1-2 N0-1 M0 breast cancer between 1990 and 2007 who underwent either BCT (lumpectomy and radiation treatment) or mastectomy. Multivariable analysis as well as a matched pair analysis were performed to compare overall survival (OS) and cause-specific survival (CSS) of patients undergoing BCT and mastectomy. Results: 14,760 women were identified, of whom 45% received BCT and 55% received mastectomy. Median follow-up was 5.7 years (range: 0.5 to 17.9 years). Multivariable analysis revealed year of diagnosis, age, race/ethnicity, grade, PR status, tumor size, number of lymph nodes positive, and number of lymph nodes examined were independent predictors of OS and CSS while ER status was of borderline significance. After accounting for all patient and tumor characteristics, multivariable analysis found that BCT resulted in similar OS (HR: 0.93; CI: 0.83-1.04; p = 0.16) and CSS (HR: 0.93, CI: 0.83-1.05; p = 0.26) as mastectomy. Matched pair analysis, including 4,644 BCT and mastectomy patients, confirmed no difference in OS or CSS: the 5/10/15-year OS for BCT and mastectomy were 92.5%/83.5%/77.0% and 91.9%/83.6%/79.1%, respectively (p = 0.99) and the 5/10/15-year CSS for BCT and mastectomy were 93.3%/85.5%/79.9% and 92.5%/85.5%/81.9%, respectively (p = 0.88). Conclusions: Young women with early-stage breast cancer have equivalent survival whether treated with BCT or mastectomy. These patients should be counseled appropriately regarding their treatment options, and should not choose a mastectomy based on the assumption of improved survival.
Abstract 1454: Patient-derived xenograft model using peritoneal fluid of gastric cancer patients
Authors: Jeong Min Kim, Won Suk Lee, Woo Sun Kwon, Han Na Park, Hye Rin Lee, Hyun Myong Kim, Tae Soo Kim, Hyunki Kim, Jae Kyung Roh, Hyun Cheol Chung, Sun Young Rha
Journal: Cancer Research (2015)

Abstract Peritoneal metastasis is the most frequent pattern of recurrence in patients with gastric cancer (GC). Patient derived xenograft (PDX) models using peritoneal fluid have been required to understand its biology and for the drug screening. So, we established the PDX model by peritoneal fluid in stage IV GC patients. First, we confirmed the preparation condition of peritoneal fluid cells for PDX model as approximately 1×107 cells in PBS. Then, we observed the engraftment rate of PDX which was 15.8% (3 of 19 patients, P2, P10 and P11). The time to 100 mm3 tumor size at F1 of 3 models was 47 ± 1, 26.7 ± 0.6 and 68 days respectively. Then, we checked the change of serial engraftment rate until F3. The more passage was progressed, the higher engraft rate was, 75% (3 of 4 mice) to 90% (9 of 10 mice) at P2, 60% (3 of 5 mice) to 85% (17 of 20 mice) at P10 and 33.3% (1 of 3 mice) to 86.7% (13 of 15 mice) at P11. In addition, time to 100mm3 tumor size of engrafted PDXs was faster at F3 than F1 in all 3 cases (41.1% in P2, 46.4% in P10 and 47.5% in P11). Also, tumor doubling time showed decreased in all engrafted PDXs according to passage (70.8% in P2, 11.5% in P10 and 71.5% in P12). Then, we checked the re-engraftment rate after thawing the frozen F3 tissue section of P2. F4 PDXs were re-engrafted 100% (3/ 3 mice) after thawing, and time to 100mm3 tumor size and tumor doubling times were not different between F3 and F4. It means that freezing and thawing of tumor fragment did not affect to engraft. After that, we compared the characterization of F0 peritoneal fluid of patient, F1∼F3 PDX tumor and the cell line established from F0. The morphologies of them were comparable by H&amp;E staining. Also, molecule expressions ofF0 to F3 and cell lines were analogous. The genetic alterations according to passages in F0 to F3 are on-going. As a result, we observed PDX from peritoneal fluid of advanced gastric cancer is feasible but various according to each patient. The PDX model by peritoneal fluid of GC patients might be helpful the biological understanding and drug development for personalized therapies. Citation Format: Jeong Min Kim, Won Suk Lee, Woo Sun Kwon, Han Na Park, Hye Rin Lee, Hyun Myong Kim, Tae Soo Kim, Hyunki Kim, Jae Kyung Roh, Hyun Cheol Chung, Sun Young Rha. Patient-derived xenograft model using peritoneal fluid of gastric cancer patients. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1454. doi:10.1158/1538-7445.AM2015-1454
The effect of pulmonary function testing on bleomycin dosing in germ cell tumors.
Authors: B. B. Houghton, P. S. Grimison, G. C. Toner, M. Chatfield, D. B. Thomson, M. Friedlander, V. Gebski, M. Rosenthal, H. Gurney, M. Stockler
Journal: Journal of Clinical Oncology (2011)

227 Background: Lung function testing (LFT) during chemotherapy with bleomycin is controversial. We describe the impact of LFT on bleomycin dosing in a phase II trial of accelerated BEP for advanced germ cell tumors. Methods: Patients had measurable disease and were stratified with the International Germ Cell Cancer Consensus Classification (IGCCC). The planned number of weekly bleomycin doses was 12 for intermediate risk (IR) and poor risk (PR) disease, and 9 for good risk (GR) disease. Clinical assessments, CXR, DLCO corrected for haemoglobin, and FVC were done 2-weekly. Bleomycin was to be stopped for: predefined clinical or CXR evidence of pulmonary toxicity; or a &gt;25% reduction in DLCO or FVC; or GFR &lt;35mL/min. We determined bleomycin doses planned, received, and omitted; and, patients receiving all, ≥2/3, or &lt;2/3 of their planned bleomycin doses. Results: The first 30 patients had a median age of 28 (range 19-39) and 10 with lung metastases. 80% (259/324) of planned bleomycin doses were received; 75 doses (20%) were omitted in 15 pts, all for &gt;25% reduction in DLCO. 16 patients had a 10 to 24% reduction in DLCO but none had &gt;35%. In all patients the decline in FVC was &lt; 10%. No patient developed other evidence of pulmonary toxicity. Patients with lung metastases were 2.5 times as likely to have a &gt;25% reduction in DLCO (50% vs 20%, p=0.15), and 4 times as likely to receive &lt;2/3 of their planned doses (40% v 10%, p=0.14). Conclusions: Asymptomatic reductions in DLCO caused 20% of bleomycin doses to be omitted and 20% of patients to receive &lt; 2/3 of their planned doses. A 25% reduction in DLCO may be too cautious a threshold, particularly in those with lung metastases. [Table: see text] No significant financial relationships to disclose.
A Switch in Regulatory T-Cell Memory Phenotype Is Associated with Poor Survival in Lower Risk Myleodysplastic Syndrome Patients
Authors: Adam W Mailloux, Chiharu Sugimori, Rami S. Komrokji, Jaroslaw P. Maciejewski, Ronald Paquette, Thomas P. Loughran, Alan F. List, P.K. Epling-Burnette
Journal: Blood (2011)
The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation
Authors: Frederick L Locke, Joseph Pidala, Barry Storer, Paul J. Martin, Michael A Pulsipher, Thomas Chauncey, Niels Jacobsen, Nikolaus Kroeger, Irwin Walker, Mary C Territo, Susan Light, Ginna G Laport, Auayporn Nademanee, Raymond Powles, Armand Keating, Gerard Socie, Claudio Anasetti
Journal: Blood (2012)
Abstract 2186: Loss Of Sfrp-1 Increases Nuclear Translocation of Beta-Catenin and Thioredoxin in the Heart Leading to Dilated Cardiomyopathy
Authors: Susan H Kwon, Robert Foronjy, Jie Sun, Peter Bodine, Jeanine M D’Armiento
Journal: Circulation (2007)

Secreted frizzled related proteins (sFRPs) inhibit the Wnt pathway which is critical for wound healing post myocardial infarction, cardiac hypertrophy and vascular angiogenesis. To understand the role of sFRP-1 in the heart, mice lacking the sFRP-1 gene were followed over a course of one year and compared to age-matched littermate wild-type mice (WT). As previously reported, the hearts of the sFRP-1 knockout (KO) mice were normal at three months of age; however, at 6 months of age, the KO mice developed hypertrophic changes with an increase in the heart/body weight and LV posterior wall thickness compared to age-matched WT mice. Furthermore, at one year of age, the KO mice developed LV chamber dilation when compared to WT mice with worsened LV systolic function and decreased diastolic function. There was increased interstitial and perivascular fibrosis in the KO mice at one year of age without change in proliferation. To determine how sFRP-1 impacted on signaling pathways linked to cardiac hypertrophy and failure, heart tissue of three month and one year old KO and WT mice was compartmentalized into cytosolic and nuclear fractions and analyzed for changes in MAPK activation, Wnt and thioredoxin signaling. Loss of sFRP-1 in the heart had no effect on MAPK proteins (p38, ERK, JNK); however, it significantly increased nuclear translocation of β-catenin and thioredoxin both at 3 months and 1 year of age. Coincident with the development of cardiac failure, increased levels of reactive nitrogen species (RNS) were observed at 1 year in the KO compared to WT mice (KO/n=6, 3.2 ±0.34 vs. WT/n=8, 2.2 ±0.30, p=0.0136). This study demonstrates for the first time that sFRP-1 regulates nuclear translocation of beta-catenin and thioredoxin in the heart, two key transcriptional regulators that have been linked to heart failure. These altered signaling events predate the development of cardiac decompensation and increased oxidative stress. Future studies will examine the downstream targets of beta-catenin and thioredoxin that mediate these physiologic changes. Further understanding the role of sFRP-1 in the heart and how it regulates the Wnt signaling and antioxidants may elucidate new insights into novel therapeutic targets in the management of heart failure patients.
A phase II open-label trial to evaluate the efficacy and toxicity of erlotinib in women with metastatic, hormone receptor-negative, and HER2-negative breast cancer.
Authors: R. D. Rao, K. P. Siziopikou, M. A. Cobleigh
Journal: Journal of Clinical Oncology (2011)

296 Background: There is limited success with current therapies for triple negative (TN) breast cancer. Epidermal growth factor receptor (EGFR) is a therapeutic target in solid tumors. Overexpression of EGFR has been linked to an aggressive breast tumor phenotype with a poor prognosis. Previous work at RUSH showed that 64% of 66 TN tumors were EGFR positive (Siziopikou SABCS 2004). To date, the use of EGFR tyrosine kinase inhibitors (TKIs) in metastatic breast cancer (MBC) has been disappointing. These trials enrolled refractory patients and did not select for EGFR expression. We hypothesized that if selected for EGFR expression, there may be a cohort of TN MBC patients who benefit from an EGFR TKI. This is a phase II study of erlotinib in TN-EGFR-positive MBC. Methods: Eligible patients had TN-EGFR-positive MBC. EGFR positivity was defined as staining in &gt;10% of tumor cells by IHC (Dako). Patients required measurable disease, prior treatment with anthracycline and taxane (adjuvant or metastatic setting) and ≤1 prior chemotherapy for MBC. Patients received erlotinib 150mg daily. Primary endpoint was progression-free survival (PFS). Initially, 18 patients were to be accrued. If ≥ 3 patients were progression-free at 4 months, accrual would continue to 43. Results: The study was terminated prematurely due to poor accrual. In total, 11 patients enrolled, 10 were treated. Mean age 56.7y, 18% African-American. Four patients had prior chemotherapy for MBC. Most patients progressed rapidly, median PFS was 29 days (95% CI 25.90 – 32.10). However, 2 patients had stable disease for 225 and 476 days. Treatment was well-tolerated. Toxicities in the 2 patients with stable disease included grade 2 rash, grade 1 diarrhea, grade 1 nausea, grade 2 weight loss and grade 1 diarrhea. Conclusions: Although most patients progressed rapidly, 2/10 patients had prolonged stable disease. This suggests there may be a subset of TN, EGFR positive MBC for whom EGFR-directed therapy may be suitable or that the natural history of their disease was indolent. Future studies to determine molecular and clinical profiles of patients likely to benefit from EGFR-TKI therapy in this population are warranted.
Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis
Authors: David J Irwin, Murray Grossman, Daniel Weintraub, Howard I Hurtig, John E Duda, Sharon X Xie, Edward B Lee, Vivianna M Van Deerlin, Oscar L Lopez, Julia K Kofler, Peter T Nelson, Gregory A Jicha, Randy Woltjer, Joseph F Quinn, Jeffery Kaye, James B Leverenz, Debby Tsuang, Katelan Longfellow, Dora Yearout, Walter Kukull, C Dirk Keene, Thomas J Montine, Cyrus P Zabetian, John Q Trojanowski
Journal: The Lancet Neurology (2016)
Percutaneous transhepatic biliary drainage (PTBD) in patients (pts) with advanced solid malignancies: Clinical outcomes and prognostic factors.
Authors: Marcela Alves Teixeira Crosara, Milena P. Mak, Daniel Fernandes Marques, Fernanda C. Capareli-Azevedo, Paulo Marcelo Hoff
Journal: Journal of Clinical Oncology (2012)

315 Background: Obstructive jaundice (OJ) is a cumbersome complication in pts with advanced digestive malignancies, and PTBD is often used to relieve symptoms and allow chemotherapy (CT) administration. Methods: From July 2008 to August 2011, a total of 71 pts with OJ due to advanced solid malignancies underwent PTBD in our institution. Baseline characteristics, procedure complications and outcome were retrospectively collected. The primary goal was to estimate overall survival (OS) after PTBD. Results: Patients’ median age was 60 years old, 52% were male, 72% had an ECOG performance status (PS) of 1-2 and 10% were in supportive care (SC). Most had metastatic disease at diagnosis (59.2%) and primary gastrointestinal tumors (biliary tract 42.3%, gastric 18.3%, colorectal 11.3%, pancreas 16.9% and 11.3% other sites). Mean hospital stay was 16.6 days (2-90), with bilirubin value decreased (BVD) in 80% of pts. The rate of cholangitis following PTBD was 66.2% and 60.6% of pts had readmissions related to procedure complications. Only 51.6% of pts not in SC were eligible for CT after PTBD. Median OS was 2.9 months (95% CI: 0.62-5.2). Prognostic factors on univariate analysis were ECOG ≤2 (13 versus 0.72 months p&lt;0.0001); BVD (6.7 versus 0.33 months p&lt;0.0001); CT after PTBD (13.7 versus 1.2 months p&lt;0.0001). SC was a negative prognostic factor (0.8 versus 4.5 months p&lt;0.0001). On the multivariate analysis, palliative CT after procedure was related to better OS (HR 0,16 CI: 0.05-0.48 p&lt;0.001). Conclusions: Malignant OJ is a late, and often final event in cancer pts. Thorough evaluation is needed before determining pts eligibility to PTBD, due to its high complication and hospitalization rates. In the current analysis, pts with PS &gt;2 and who are not candidates for further CT had a dismal prognosis, and should probably not be offered PTBD.
Clustered Papulovesicles in a Fully Vaccinated Child
Authors: Emily A. Simons, Allen W. Ho, Jennifer T. Huang
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Azacitidine Overcomes Prognosis Impact of Poor and Very Poor IPSS-Revised in RAEB-2 Patients but Not in AML Patients.
Authors: Thomas Cluzeau, Nicolas Mounier, Valentine Richez, Jean-Michel Karsenti, Faezeh Legrand, Lionel Mannone, Henri Vinti, Laurence Legros, Lauris Gastaud, Antoine Thyss, Georges Garnier, Daniel Re, Nathalie Montagne, Jean Gutnecht, Patrick Auberger, Sophie Raynaud, Jill-Patrice Cassuto
Journal: Blood (2012)
Pretransplantation Myeloablative Conditioning Regimen with Intravenous Busulfan Dose Adjustment for Older Patients with Hematologic Malignancies
Authors: Sabine Fürst, Jean El Cheikh, Bénédicte Devictor, Sandra Cournier, Angela Granata, Samia Harbi, Raynier Devillier, Faezeh Legrand, Stefania Bramanti, Claude Lemarie, Jean Pierre Weiller, Catherine Faucher, Christian Chabannon, Borje S. Andersson, Didier Blaise
Journal: Blood (2016)
Preliminary safety results of an ongoing phase I/II clinical study of MGN1601, a tumor vaccine comprising allogeneic, gene-modified, and irradiated tumor cells in combination with an immunomodulator in patients with metastatic renal cell carcinoma (ASET study).
Authors: M. Tschaika, S. Weikert, V. Gruenwald, I. Schmidt-Wolf, M. Schroff, B. Wittig, M. Schmidt
Journal: Journal of Clinical Oncology (2011)

392 Background: MGN1601 is a cell-based RCC tumor vaccine MGN1601 consisting of two active pharmaceutical ingredients: genetically modified allogeneic (human) cells transfected with four different MIDGE vectors encoding IL-7, GM-CSF, CD80 and CD154 and a synthetic DNA-based immunomodulator dSLIM-30L1, a TLR-9 agonist. The vaccine is being developed for treatment of patients with advanced RCC. Its prophylactic and therapeutic anti-tumor activity has been shown in several in-vivo models. A good safety profile of MGN1601 was shown in a wide program of acute and chronic toxicity studies. Based on these promising data, this phase 1/2 study was started in patients with advanced RCC. Methods: This multicentric open clinical study for the assessment of safety and efficacy of MGN1601 in patients with advanced RCC was initiated in October 2010. A total of 24 patients have to be recruited into the study. The treatment consists of 8 MGN1601 treatments administered as follows: the first 3 treatments are administered on a weekly basis, and the consecutive 5 treatments on a bi-weekly basis. The treatment dose contains 10 7 transfected tumor cells and 5 mg dSLIM per administration, which has been proven to be safe with a high safety margin in repeated toxicity studies. The efficacy and safety of the study treatment will be evaluated based on extensive immunological tests, radiological assessment, safety laboratory results and assessments of the quality of life. Here, the first safety data are presented. [Table: see text]
68Ga-PSMA PET/CT Imaging in Multiple Myeloma
Authors: Arun Sasikumar, Ajith Joy, M.R. A. Pillai, Raviteja Nanabala, Boben Thomas
Journal: Clinical Nuclear Medicine (2016)

The potential applications of Ga-labeled prostate-specific membrane antigen (PSMA) PET/CT in the imaging of prostate cancer are now well established. A few case reports regarding the potential use of Ga-PSMA PET/CT in nonprostate cancer malignancies are also published. Apparently, the tumor neoangiogenesis is the mechanism attributed to increased Ga-PSMA uptake in the tumor sites in nonprostatic malignancies. We describe the use of Ga-PSMA PET/CT in imaging multiple myeloma. The intense Ga-PSMA avidity of the lesions also opens up the possibility of theranostics with Lu-PSMA.